Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New drug can restore social ability in schizophrenics

06.12.2007
The social behaviour of rats displaying schizophrenic tendencies is restored when they are treated with two new potential drugs that seem to have unique effects on dopaminergic signalling. This is a conclusion of a thesis from the Sahlgrenska Academy at Göteborg University in Sweden.

Schizophrenia is a severe psychiatric disorder with symptoms that include hallucinations and delusions. Other common effects are social withdrawal, lack of initiative, dulled emotions, and difficulty in experiencing pleasure.

"The treatment available for schizophrenic patients hardly ever relieves impairment of social function. If patients are to have satisfactory lives, we must find new drugs," says pharmacologist Johan Rung, who has studied the two drug candidates, OSU6162 and ACR16.

In the studies, rats were given a type of drug known for inducing a schizophrenia-like state in humans, and this reduced the rats' social behaviour. When the rats were given the two drug candidates, normal social behaviour was restored.

"This indicates that the two drugs can relieve the schizophrenic's lack of ability to interact socially, and also have positive effects on a number of other symptoms thought to be caused by the same underlying mechanisms," says Johan Rung.

In contrast to other drugs that only reduce dopaminergic signalling in the brain, the two new substances seem to be able to both reduce and strengthen the signalling, depending on the circumstances.

"This is a property that can be particularly beneficial in the treatment of schizophrenia. Different groups of symptoms can be linked to either elevated or reduced dopaminergic signalling in different parts of the brain," says Johan Rung.

More years of research lie ahead before doctors can prescribe the new substances as drugs for their patients. An international drug company has recently started to test ACR16 on patients. The other substance, OSU6162, has also been tested on a small number of schizophrenia patients, and the results are promising.

SCHIZOPHRENIA
Schizophrenia is a psychiatric disease that afflicts one percent of the population. There is no cure, but psychotic symptoms can be treated with psychopharmaceuticals. The onset usually occurs when people are in their twenties. The condition is often severe, and most patients never return to school or work.
For more information, please contact:
Johan Rung, pharmacologist, telephone: +46 (0)31-786 33 28, +46 (0)70-350 30 58, e-mail: johan.rung@psychiat.gu.se
Supervisor:
Associate Professor Maria Carlsson, telephone: +46 (0)31-786 33 28, e-mail: maria.carlsson@psychiat.gu.se
Doctor of Philosophy (Medicine) thesis at the Sahlgrenska Academy, Institute of Neuroscience and Physiology, Department of Clinical Neuroscience and Rehabilitation.

Title of thesis: Dopaminergic stabilizers for the treatment of schizophrenia; rat studies focusing on negative symptoms and mechanisms of action

Elin Lindström Claessen
Information Officer, Sahlgrenska Academy at Göteborg University
Telephone: +46 (0)31-786 3837, +46 (0)70-829 43 03
e-mail: elin.lindstrom@sahlgrenska.gu.se
The Sahlgrenska Academy is the faculty of health sciences at Göteborg University. Education and research are conducted within the fields of medicine, odontology and health care sciences. About 4,000 undergraduate students and 1,000 postgraduate students are enrolled at the Sahlgrenska Academy. The Academy has 1,500 employees, 850 of which are researchers and/or teachers.

Elin Lindström Classeb | idw
Further information:
http://www.vr.se

Further reports about: Academy Rung Sahlgrenska patients schizophrenic signalling symptoms

More articles from Life Sciences:

nachricht Transport of molecular motors into cilia
28.03.2017 | Aarhus University

nachricht Asian dust providing key nutrients for California's giant sequoias
28.03.2017 | University of California - Riverside

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A Challenging European Research Project to Develop New Tiny Microscopes

The Institute of Semiconductor Technology and the Institute of Physical and Theoretical Chemistry, both members of the Laboratory for Emerging Nanometrology (LENA), at Technische Universität Braunschweig are partners in a new European research project entitled ChipScope, which aims to develop a completely new and extremely small optical microscope capable of observing the interior of living cells in real time. A consortium of 7 partners from 5 countries will tackle this issue with very ambitious objectives during a four-year research program.

To demonstrate the usefulness of this new scientific tool, at the end of the project the developed chip-sized microscope will be used to observe in real-time...

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Transport of molecular motors into cilia

28.03.2017 | Life Sciences

A novel hybrid UAV that may change the way people operate drones

28.03.2017 | Information Technology

NASA spacecraft investigate clues in radiation belts

28.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>